Revenio Group stock

REG1V · Nasdaq Helsinki · EUR

Compare Revenio Group
€9.04Change from previous close: −1.74%Absolute change: −€0.16

Close · November 20, 2026

Price history

−59.28% over the period

1 year: from €22.20 (November 20, 2025) to €9.04 (November 20, 2026), −59.28%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€9.04
October 30, 2026€10.38
September 30, 2026€10.68
August 31, 2026€14.94
July 31, 2026€12.22
June 30, 2026€12.20
May 29, 2026€13.96
April 30, 2026€13.90
March 31, 2026€18.96
February 27, 2026€18.60
January 30, 2026€20.05
December 30, 2025€22.40
November 28, 2025€22.30
November 20, 2025€22.20

At a glance

  • The company

    Develops ophthalmological devices and software for diagnosing glaucoma, macular degeneration, and diabetic retinopathy

  • Latest results

    Quarter to September 30, 2026 · EPS €0.15 (estimate €0.08)

TickerLandia's take on Revenio Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€8.74
52-wk high€23.40

−61.37% from the 52-week high

Analysts · 4 analysts

Average target€11.68+29.15% vs. price

Buy 3 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Revenio Group

Compared with similar companies: very weak momentum and very high risk.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Revenio Group is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Revenio Group's P/E today is 13.8, below the median of its last 10 fiscal years (41.5; between 34.2 and 100.2 from 2016 to 2025). Revenio Group's P/E (trailing 12 months): 25.1, −13% against the median of a group of 10 similar companies (28.9).

P/E compared with its history

Compared with 10 similar companies

Revenio Group's metrics compared with similar companies
MetricRevenio GroupPosition in the groupBand
P/E (trailing 12 months)25.1Low
Forward P/E14.8Low
Operating margin14.1%Middle
ROE10.3%Middle
Debt/equity1.73High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Revenio Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€59M

Latest quarter · Q3 2026

Net income

€3.4M

Latest quarter · Q3 2026

Quarterly net margin

5.8%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€390.23M
P/E
25.1
EPS
€0.37
Volume
201.83K
Daily trading
€960.99K

How Revenio Group is changing

All results
  • Revenue grew 12.4% a year on average over the last 5 years

  • Operating margin fell from 30.5% to 23.1%

  • Profits turn into cash: free cash flow equal to 113% of net income

Returns

Revenio Group returns with dividends

€1,000 invested in Revenio Group 5 years ago, on November 22, 2021, would be worth €169 today with dividends reinvested: −83.11% in total, −29.96% per year. On price alone it would be €161 (−83.91%).

PeriodRevenio Group€1,000 becomes
1 month−18.26%€817
6 months−35.70%€643
Year to date−59.64%€404
1 year−59.28%€407
3 years−60.80%€392
5 years−83.11%€169
10 years+23.99%€1,240

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Revenio Group: technical analysis

Revenio Group is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 87.2% below its all-time closing high (€70.70, August 4, 2021).

Trend
Downward
RSI (14 sessions)
32
Between 30 and 70
vs 200-session average
−35.18%

Support and resistance

Price areas where Revenio Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€13.35+47.71%3 touches, last on May 13, 2026
  2. Resistance€11.91+31.78%3 touches, last on October 14, 2026
  3. Resistance€10.29+13.83%2 touches, last on October 27, 2026
  4. Last price€9.04
  5. No support below: the price is near the lows of the year

Volatility and risk

Volatility (60 sessions, annualised)
71.5%
Largest fall in the last year
−61.04%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Revenio Group: seasonality

Average monthly price change over 25 years

+4.4%Jan+1.3%Feb+1.2%Mar+2.3%Apr+3.4%May−0.7%Jun+2.5%Jul−0.1%Aug−2.8%Sep+0.5%Oct+4.2%Nov+1.4%Dec

Over the last 25 years, the strongest month for Revenio Group has been January: +4.35% on average, positive in 13 years out of 25. The weakest has been September: −2.79% on average, positive in 9 years out of 25. November, the current month, has been positive in 14 years out of 25 (+4.19% on average).

Show chart data
MonthAverageMedianPositive years
January+4.35%+2.78%13 of 25
February+1.32%0.00%11 of 25
March+1.25%+0.39%13 of 25
April+2.29%+2.75%13 of 25
May+3.42%−1.88%11 of 25
June−0.74%0.00%11 of 25
July+2.48%+1.45%15 of 25
August−0.15%−3.12%9 of 25
September−2.79%−0.64%9 of 25
October+0.53%0.00%11 of 25
November+4.19%+3.70%14 of 25
December+1.42%0.00%10 of 25

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Revenio Group and its competitors

The iCare tonometer range, including the iCare HOME2 for measuring eye pressure at home and the TONOVET models used in surgical settings and by veterinarians, forms the core of the product line of Revenio Group Oyj. Alongside these devices the company sells imaging equipment such as iCare EIDON and iCare COMPASS, and software including iCare ILLUME, which uses artificial intelligence to screen for early signs of eye disease, iCare CLINIC for long-term pressure records, and the Oculo platform for telehealth and remote patient monitoring.

Headquarters
Vantaa, Finland
Employees
765
Founded
2001
Chief executive
Jouni Toijala
Revenio Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Revenio GroupREG1V$428.87M14.1%25.1−35.70%
Synektik Spólka AkcyjnaSNT$647.15M23.3%15.9+9.15%
El.En.ELN$1.44B14.7%20.7+10.78%
ChemoMetecCHEMM$1.75B49.1%59.9+99.42%
ElektaEKTA.B$2.27B9.2%—+1.17%
Medacta GroupMOVE$2.41B15.2%27.7−30.49%

Same industry or related industries, similar size. Compare Revenio Group with its competitors · Full profile